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Background:   
Huntington’s disease (HD) is a complex neurodegenerative condition that calls for a multifaceted 
approach to patient care. Multidisciplinary team (MDT) meetings are one tool by which the expertise 
of multiple professionals can be focused into the care of a patient, combining the knowledge and 
expertise required to deliver the best management plan.  
Aims:  
To estimate the time and monetary costs of a HD MDT meeting held after a specialist HD clinic, and 
its value to patient care. 
Methods:  
This study was authorized by the department’s Audit Lead, as stipulated by the UCLH/UCL NHS 
Trust, London, UK. Data were prospectively retrieved from HD MDT meetings at the National Hospital 
for Neurology and Neurosurgery from February to June 2016. 
To ascertain cost, at each meeting, staff members registered their name, position and time spent to 
prepare the meeting. All patients attending the HD Multidisciplinary Specialist Clinic were included in 
this study; the time spent to discuss each patient was recorded, as was age, gender and diagnostic 
stage. To evaluate the value, the number and type of changes to management plans, performed as a 
result of the MDT discussion, were recorded. 
The cost per unit of time -- estimated based on midlevel salary for each of the healthcare 
professionals involved -- was multiplied by the time each staff member spent preparing and attending 
the meeting. The annual cost was computed by means of the average cost per patient, the frequency 
of the meetings (26 per year) and the average number of patients discussed per meeting. 
Results: 
Six meetings, comprising 92 patients (mean age 52 years; 58% males; 15% pre-manifest, 52% early 
HD, 22% moderate HD, 11% advanced HD) were analyzed. Each meeting had a median duration of 
41.33 minutes, a median of 14.5 patients, and a mean total cost of 451 GBP. Each patient was 
discussed for an average of 2:34 minutes, costing 30 GBP, and no difference was found between 
gender, age or stage. The estimated annual cost of this MDT meeting was £11474 GBP. More than 
40% of draft management plans experienced a change as a result of the MDT discussion, a cost of 
£12 per change of plan. 
Conclusions:   
Our study demonstrates that HD MDT meetings bring significant value to the management plan of 
patients at a modest cost. Still, further multicentre outcome-focused studies are needed to ascertain 
cost-effectiveness. 
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